Alectinib - National Cancer Institute

Alectinib - National Cancer Institute



New Drug for Non-Small Cell Lung Cancer 

A new summary about the drug alectinib. It was recently approved by the Food and Drug Administration (FDA) to treat non-small cell lung cancer in certain patients.

Alectinib

• 
• 
• 
• 
• 
• 
• 

(uh-LEK-tih-nib)

This page contains brief information about alectinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Alecensa

FDA Approved

Yes

FDA Approval for Alectinib

Use in Cancer

Alectinib is approved to treat:

• Non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used in patients whose cancer has a mutation in the anaplastic lymphoma kinase (ALK) gene and who cannot be treated with crizotinib or have gotten worse while taking it.

More About Alectinib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Alectinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

Alectinib - National Cancer Institute